Abstract
The shift from traditional chemotherapy to more targeted therapies has been a landmark change in chronic lymphocytic leukemia (CLL) treatment. This transformation has implications for treatment efficacy, tolerability, and patient quality of life, along with implications for the Canadian oncology community at large, which must rapidly adapt to these advancements. This rapid development underscores the importance of continued responsiveness in medical practice, including more collaborative work with Canadian institutions and provincial cancer care to deliver these transformative therapies to patients. This review aims to offer practical guidance, from a Canadian perspective, for clinicians in treatment selection in the era of targeted therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
